Assessing Natera (NTRA) valuation after new Signatera breast cancer study results. April 04, 2026 Why the latest Signatera study matters for Natera (NTRA) shareholders. Natera (NTRA) is back in focus after publishing new Clinical Cancer Research data on its Signatera test, showing how older women with early stage ER+/HER2- breast cancer might be treated with endocrine therapy alone. The prospective study followed women aged 70 and above who chose to skip surgery and receive primary endocrine therapy, with Signatera used regularly alongside imaging and physician assessments to track molecular residual disease and inform care decisions. The new Signatera data lands after a volatile stretch for Natera, with the share price at US$207.98, a 7 day share price return of 13.87% and a 90 day share price return decline of 9.12%, alongside a 1 year total shareholder return of 55.36% and a 3 year total shareholder return of about 3x. This combination of metrics suggests that recent momentum has cooled compared with the longer term record. If this kind of healthcare technology story interests you, it could be worth widening your search to other potential opportunities using the 36 healthcare AI stocks With Natera trading at US$207.98, carrying a value score of 4 and flagged as trading below some intrinsic estimates, the real question is whether you are seeing a genuine mispricing or a market that is already factoring in future growth. On the most followed narrative, Natera's fair value of $260.65 sits well above the $207.98 last close, putting a lot of weight on long term execution. Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion. Curious what earnings, revenue growth, and margin profile are baked into that gap between price and fair value? The narrative leans on bold compounding assumptions and premium future multiples that many investors will want to scrutinize closely. Result: Fair Value of $260.65 (UNDERVALUED) However, there are clear pressure points here, including ongoing net losses of $208.16m and heavy R&D and SG&A spend that could delay any path to profitability. Next steps. With the story so mixed, it makes sense to look at the full picture yourself and act while sentiment is still shifting. Start with the 3 key rewards. Looking for more investment ideas? If Natera has caught your attention, do not stop here, widen your watchlist now so you are not relying on a single story to shape your returns. * Target potential mispricings by scanning companies that combine quality fundamentals with appealing valuations using the 59 high quality undervalued stocks. * Prioritize resilience by reviewing companies that stand out on stability and risk scoring with the 68 resilient stocks with low risk scores. * Spot less crowded opportunities by using the screener containing 25 high quality undiscovered gems before everyone else starts paying attention. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Valuation is complex, but we're here to simplify it. Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Natera SEC. sold $1.7m in NTRA stock. Published 04/03/2026, 09:10 PM Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sales, totaling $1.7 million, occurred at weighted average prices ranging from $200.7868 to $205.0026 per share.The insider sale comes as Natera's stock has surged 55% over the past year, currently trading at $207.98 with a market capitalization of $29.48 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the Most Overvalued list. The filing indicates that the shares were sold in multiple transactions, with prices ranging as follows: 300 shares were sold between $200.47 and $200.99, 1,778 shares were sold between $201.4950 and $202.4700, 3,213 shares were sold between $202.51 and $203.46, 1,200 shares were sold between $203.52 and $204.25 and 1,909 shares were sold between $204.54 and $205.50. Following the reported transactions, Rabinowitz directly owns 224,885 shares of Natera, Inc. common stock. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.InvestingPro subscribers have access to 8 additional exclusive tips for NTRA, plus comprehensive Pro Research Reports covering over 1,400 US equities. In other recent news, Natera Inc. has launched Zenith genomics, a whole genome sequencing test aimed at detecting rare genetic conditions. This new test employs advanced long-read sequencing technology to identify complex genetic features, developed in collaboration with MyOme. Additionally, Natera's Signatera circulating tumor DNA assay has shown promising results in studies on anal squamous cell carcinoma and locally advanced rectal cancer, with significant findings published in Nature Communications. The studies demonstrated 100% one-year overall survival and progression-free survival for certain patients, highlighting the potential of the Signatera test in cancer treatment monitoring. Furthermore, Natera has expanded its board of directors by appointing Eric Rubin, increasing the board size to eleven members. This appointment was recommended by the Nominating, Corporate Governance and Compliance Committee. In terms of financial analysis, Morgan Stanley has adjusted its model for Natera, reducing the stock price target to $250 from $265 while maintaining an Overweight rating. These developments reflect Natera's ongoing efforts to innovate in genetic testing and expand its leadership team. What are the best investment opportunities in 2026? The best investments start with better data. Going with your gut has its place, but when excitement masquerades as intuition, it can lead to costly mistakes - or analysis paralysis. InvestingPro+ combines institutional-grade data with AI-powered insights that you don't need a finance PhD to understand. It won't guarantee winners, but it will certainly help you find more of them, more often. So what are the best investments of 2026 so far?

Natera named Healthcare Technology Company of the Year. Published. March 17, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo had the privilege of recognizing several exceptional companies driving innovation across healthcare technology. Congratulations to Natera on being named Healthcare Technology Company of the Year. Natera is a global leader in cell-free DNA (cfDNA) testing, advancing precision medicine across oncology, women's health, and organ health. Through its proprietary molecular and bioinformatics technologies, the company enables highly sensitive, non-invasive genetic testing designed to help clinicians detect disease earlier. From tumor-informed cancer monitoring to prenatal genetic screening and transplant assessment technologies, Natera continues to expand what's possible in molecular diagnostics - supporting more informed care decisions and better outcomes for patients and families. Representing the company at the event, Oded Wohl, Vice President of Product Management, accepted the award on behalf of the Natera team., Oded shared: "One of our core values at Natera is 'a patient behind every sample.' This carries great weight, as we all know that each sample processed in our lab represents an individual or family seeking answers for their care. We take this very seriously. We accept this award on their behalf, along with the more than 6,000 employees at Natera who are deeply committed to the same mission." Please join The Healthcare Technology Repo in congratulating the Natera team on this well-deserved recognition. Picture: Oded Wohl speaks at NYC Awards Night The Healthcare Technology Report is your comprehensive source for business news, investment activity and corporate actions related to the healthcare technology industry.